Latest Insider Transactions at Vir Biotechnology, Inc. (VIR)
This section provides a real-time view of insider transactions for Vir Biotechnology, Inc. (VIR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vir Biotechnology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vir Biotechnology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2022
|
Steven J. Rice Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
1,942
-9.43%
|
$60,202
$31.93 P/Share
|
|
Feb 17
2022
|
George A Scangos Director |
SELL
Open market or private sale
|
Direct |
10,024
-7.12%
|
$310,744
$31.93 P/Share
|
|
Feb 17
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,293
-2.13%
|
$71,083
$31.93 P/Share
|
|
Feb 17
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,009
-3.24%
|
$93,279
$31.93 P/Share
|
|
Feb 16
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.11%
|
$155,000
$31.54 P/Share
|
|
Feb 16
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Feb 08
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$45,375
$33.94 P/Share
|
|
Feb 08
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Feb 02
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.11%
|
$170,000
$34.52 P/Share
|
|
Feb 02
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Jan 25
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$44,000
$32.46 P/Share
|
|
Jan 25
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Jan 19
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.59%
|
$175,000
$35.06 P/Share
|
|
Jan 19
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Jan 18
2022
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,173
-0.98%
|
$561,401
$37.39 P/Share
|
|
Jan 11
2022
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$48,125
$35.1 P/Share
|
|
Jan 11
2022
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Jan 05
2022
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.57%
|
$185,000
$37.46 P/Share
|
|
Jan 05
2022
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Dec 28
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$53,625
$39.95 P/Share
|
|
Dec 28
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Dec 20
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
61,207
+28.46%
|
-
|
|
Dec 20
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,750,000
-8.47%
|
-
|
|
Dec 20
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
102,041
+29.47%
|
-
|
|
Dec 20
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
1,750,000
-8.47%
|
-
|
|
Dec 20
2021
|
Svf Endurance (Cayman) LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,022
-1.77%
|
$20,801,144
$52.73 P/Share
|
|
Dec 20
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.19%
|
$834,570
$55.1 P/Share
|
|
Dec 15
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-1.3%
|
$250,000
$50.88 P/Share
|
|
Dec 15
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.86%
|
$5,000
$1.53 P/Share
|
|
Dec 15
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,750
-2.49%
|
$137,500
$50.0 P/Share
|
|
Dec 15
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+2.43%
|
$2,750
$1.53 P/Share
|
|
Dec 14
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
1,375
-1.26%
|
$61,875
$45.88 P/Share
|
|
Dec 14
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+1.24%
|
$1,375
$1.53 P/Share
|
|
Dec 01
2021
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,500
-1.91%
|
$322,500
$43.59 P/Share
|
|
Nov 30
2021
|
Janet Napolitano Director |
SELL
Open market or private sale
|
Direct |
1,435
-29.84%
|
$66,010
$46.25 P/Share
|
|
Nov 30
2021
|
Janet Napolitano Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,435
+22.98%
|
$58,835
$41.64 P/Share
|
|
Nov 30
2021
|
Steven J. Rice Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
10,000
-32.68%
|
$500,000
$50.0 P/Share
|
|
Nov 30
2021
|
Steven J. Rice Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.63%
|
$120,000
$12.76 P/Share
|
|
Nov 30
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
15,125
-6.22%
|
$710,875
$47.8 P/Share
|
|
Nov 30
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,125
+10.96%
|
$15,125
$1.53 P/Share
|
|
Nov 29
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
17,485
+15.87%
|
-
|
|
Nov 29
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-2.36%
|
-
|
|
Nov 29
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
29,153
+17.02%
|
-
|
|
Nov 29
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-2.36%
|
-
|
|
Nov 29
2021
|
Ann M. Hanly EVP & Chief Technology Officer |
BUY
Open market or private purchase
|
Indirect |
11
+50.0%
|
$473
$43.39 P/Share
|
|
Nov 26
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
15,174
-0.96%
|
$546,264
$36.8 P/Share
|
|
Nov 22
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
17,485
+18.87%
|
-
|
|
Nov 22
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-2.31%
|
-
|
|
Nov 22
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
29,153
+20.51%
|
-
|
|
Nov 22
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-2.31%
|
-
|